Compare BridgeBio Pharma Inc (BBIO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NRG Energy Inc — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while NRG Energy Inc trades at $137.77 (market cap $29.19B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.37% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NRG | |
|---|---|---|
Market Cap | $16.46B | $29.19B |
Sector | Health | Utilities |
52-Week High | $90.17 | $184.03 |
52-Week Low | $44.81 | $120.65 |
Enterprise Value | $18.02B | $53.02B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
NRG Energy trades at $139.48, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 153.27 but attractive P/S of 0.86, while revenue grew to $30.71B in 2025. Analyst sentiment remains positive with 64% buy ratings, though technical indicators suggest near-term pressure with support at $138.
Outlook is cautiously optimistic given strong analyst support and dividend payments, but risks include high debt levels and volatile cash flows. Investors should weigh solid revenue growth against margin compression and elevated valuation multiples before positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
